Advertisement

December 2015 Briefing – Allergy

0
Here are what the editors at HealthDay consider to be the most important developments in Allergy for December 2015. This roundup includes the latest...
Timing of the diphtheria-tetanus-acellular pertussis (DTaP) vaccination is not tied to child food allergies; however

Timing of DTaP Vaccine Not Tied to Food Allergies at Age 1 Year

0
However, delayed DTaP immunization is tied to a reduction in eczema
Physician burnout is the top issue for physicians in 2015

AMA: Burnout Is Top Issue for Physicians in 2015

0
More than half of docs report at least one symptom of burnout; efforts being undertaken to address burnout
From 2001 to 2009 there was an increase in childhood asthma prevalence

Increase in Child Asthma Has Ceased Overall, but Not for Poor

0
Increase in prevalence from 2001 to 2009, which plateaued then decreased in 2013
Prices at hospitals in monopoly markets are 15 percent higher than those at hospitals in areas with at least four providers

Higher Hospital Prices in U.S. ‘Monopoly Markets’

0
Hospital prices positively associated with indicators of hospital market power
In order to prevent denials

Specific, Consistent ICD-10 Coding Key to Timely Payments

0
Tips to prevent denials include checking EHR selection against documentation, being specific
Implementation of the Affordable Care Act has improved access to care and affordability of care for many adults

Affordable Care Act Has Improved Access to Care, Affordability

0
However, gaps in access to care and affordability still seen, especially for low-income adults
For individual patients with poorly-controlled asthma

Nasal, Pharyngeal EPX Levels Linked to Sputum Eosinophilia

0
Strong correlation seen for eosinophil peroxidase levels in adults with poorly-controlled asthma
There's been a sharp rise in the number of industry-funded clinical trials and a significant decline in those financed by the U.S. government in recent years

Industry Outpacing NIH in Funding Research

0
Analysis finds studies paid for by private sector increasing, while U.S.-sponsored trials decline
Omalizumab appears to be highly effective for the management of severe allergic asthma

Omalizumab Highly Effective for Severe Allergic Asthma

0
Review of "real-life" studies shows improvements across objective and subjective burden of illness